Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2018 1
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year
Filters applied: . Clear all
Page 1
The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E-transformed cells.
Furlan T, Khalid S, Nguyen AV, Günther J, Troppmair J. Furlan T, et al. Mol Oncol. 2018 Jun;12(6):869-882. doi: 10.1002/1878-0261.12199. Epub 2018 May 5. Mol Oncol. 2018. PMID: 29624862 Free PMC article.
p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer.
Gruber M, Ferrone L, Puhr M, Santer FR, Furlan T, Eder IE, Sampson N, Schäfer G, Handle F, Culig Z. Gruber M, et al. Among authors: furlan t. Endocr Relat Cancer. 2020 Mar;27(3):187-198. doi: 10.1530/ERC-19-0488. Endocr Relat Cancer. 2020. PMID: 31951590 Free PMC article.
Novel Insights into the PKCβ-dependent Regulation of the Oxidoreductase p66Shc.
Haller M, Khalid S, Kremser L, Fresser F, Furlan T, Hermann M, Guenther J, Drasche A, Leitges M, Giorgio M, Baier G, Lindner H, Troppmair J. Haller M, et al. Among authors: furlan t. J Biol Chem. 2016 Nov 4;291(45):23557-23568. doi: 10.1074/jbc.M116.752766. Epub 2016 Sep 13. J Biol Chem. 2016. PMID: 27624939 Free PMC article.
Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP.
Hatzl S, Geiger O, Kuepper MK, Caraffini V, Seime T, Furlan T, Nussbaumer E, Wieser R, Pichler M, Scheideler M, Nowek K, Jongen-Lavrencic M, Quehenberger F, Wölfler A, Troppmair J, Sill H, Zebisch A. Hatzl S, et al. Among authors: furlan t. Cancer Res. 2016 Jun 15;76(12):3644-54. doi: 10.1158/0008-5472.CAN-15-3049. Epub 2016 Apr 15. Cancer Res. 2016. PMID: 27197200 Free PMC article.